Roivant Sciences Ltd. Common Shares vs Vanguard Information Technology Index Fund ETF — how do they compare? Roivant Sciences Ltd. Common Shares trades at $35.07 (market cap $24.72B), while Vanguard Information Technology Index Fund ETF trades at $127.74 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 6.9× Roivant Sciences Ltd. Common Shares's market cap, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Roivant Sciences Ltd. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roivant Sciences Ltd. Common Shares for 1 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| ROIV | VGT | |
|---|---|---|
Market Cap | $24.72B | $170.20B |
Volume | 6,279,442 | 5,132,883 |
Sector | Health | — |
52-Week High | $41.81 | $129.79 |
52-Week Low | $16.04 | $83.59 |
Typical Hold Time | 1 Days | 129 Days |
Enterprise Value | $20.99B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VGT trades at $127.00, down 1.83% today but maintains a bullish technical outlook with strong moving average support. The ETF's focus on pure-play technology stocks like Nvidia, Apple, and Microsoft has delivered exceptional historical returns, averaging over 17% annually for two decades according to The Motley Fool (2026-10-03). Recent institutional buying activity signals continued confidence in the tech sector's growth prospects.
While VGT offers concentrated tech exposure with low fees, investors face sector concentration risk and potential AI slowdown concerns. The ETF's exclusion of major tech names like Google and Amazon due to classification rules creates unexpected portfolio gaps. Current technical strength supports near-term upside, but macroeconomic headwinds could pressure tech valuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →